[{"address1": "11400 West Olympic Boulevard", "address2": "Suite 200", "city": "Los Angeles", "state": "CA", "zip": "90064", "country": "United States", "phone": "310 651 8041", "website": "https://www.immixbio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.", "fullTimeEmployees": 9, "companyOfficers": [{"maxAge": 1, "name": "Dr. Ilya  Rachman M.B.A., M.D., MBA, Ph.D.", "age": 49, "title": "Co-Founder, CEO & Chairman", "yearBorn": 1973, "fiscalYear": 2022, "totalPay": 637500, "exercisedValue": 0, "unexercisedValue": 43538}, {"maxAge": 1, "name": "Mr. Gabriel  Morris B.A.", "age": 36, "title": "CFO & Director", "yearBorn": 1986, "fiscalYear": 2022, "totalPay": 637500, "exercisedValue": 0, "unexercisedValue": 368275}, {"maxAge": 1, "name": "Mr. Sean  Senn J.D., M.B.A., M.Sc., MBA, MSc", "title": "Co-Founder", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Vladimir P. Torchilin D.Sc., MSE, Ph.D.", "age": 75, "title": "Scientific Co-Founder", "yearBorn": 1947, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ben H. Lyon J.D.", "title": "Executive VP & General Counsel", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Graham  Ross FFPM, M.D.", "age": 62, "title": "Chief Medical Officer & Head of Clinical Development", "yearBorn": 1960, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Nandan  Oza B.S.", "age": 60, "title": "Head of Chemistry, Manufacturing & Control", "yearBorn": 1962, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David  Marks", "title": "Chief Medical Officer of Cell Therapy", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Gerhard  Bauer", "title": "Head of Cell Thearpy Manufacturing", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 2, "previousClose": 4.17, "open": 4.27, "dayLow": 4.23, "dayHigh": 5.9699, "regularMarketPreviousClose": 4.17, "regularMarketOpen": 4.27, "regularMarketDayLow": 4.23, "regularMarketDayHigh": 5.9699, "payoutRatio": 0.0, "forwardPE": -6.3820224, "volume": 2313204, "regularMarketVolume": 2313204, "averageVolume": 240133, "averageVolume10days": 174620, "averageDailyVolume10Day": 174620, "bid": 0.0, "ask": 0.0, "bidSize": 800, "askSize": 800, "marketCap": 112845696, "fiftyTwoWeekLow": 1.4, "fiftyTwoWeekHigh": 5.9699, "fiftyDayAverage": 4.0339, "twoHundredDayAverage": 2.664185, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "enterpriseValue": 93138744, "profitMargins": 0.0, "floatShares": 8046027, "sharesOutstanding": 19867200, "sharesShort": 139706, "sharesShortPriorMonth": 294993, "sharesShortPreviousMonthDate": 1698710400, "dateShortInterest": 1701302400, "sharesPercentSharesOut": 0.0069999998, "heldPercentInsiders": 0.60138, "heldPercentInstitutions": 0.01944, "shortRatio": 0.67, "shortPercentOfFloat": 0.0108, "impliedSharesOutstanding": 19867200, "bookValue": 1.008, "priceToBook": 5.6349206, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -14136381, "trailingEps": -0.92, "forwardEps": -0.89, "enterpriseToEbitda": -6.398, "52WeekChange": 1.2063491, "SandP52WeekChange": 0.22187173, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "IMMX", "underlyingSymbol": "IMMX", "shortName": "Immix Biopharma, Inc.", "longName": "Immix Biopharma, Inc.", "firstTradeDateEpochUtc": 1639665000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "a16f90b7-2d1a-3bc1-ad13-b52d1a275ae3", "messageBoardId": "finmb_417356223", "gmtOffSetMilliseconds": -18000000, "currentPrice": 5.68, "recommendationMean": 2.0, "recommendationKey": "buy", "totalCash": 19582424, "totalCashPerShare": 0.986, "ebitda": -14556881, "totalDebt": 0, "quickRatio": 7.162, "currentRatio": 7.904, "returnOnAssets": -0.45648, "returnOnEquity": -0.78246003, "freeCashflow": -7486502, "operatingCashflow": -12597927, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "trailingPegRatio": null}]